Compare Amylx Pharmaceuticals Inc (AMLX) vs Consolidated Edison, Inc. (ED) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Consolidated Edison, Inc. — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while Consolidated Edison, Inc. trades at $110.82 (market cap $40.95B). The key difference: Consolidated Edison, Inc. is far larger — about 20.7× Amylx Pharmaceuticals Inc's market cap, and Consolidated Edison, Inc. pays a 3.13% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | ED | |
|---|---|---|
Market Cap | $1.98B | $40.95B |
Sector | Health | Utilities |
52-Week High | $18.70 | $115.46 |
52-Week Low | $7.64 | $95.37 |
Enterprise Value | $1.70B | $67.98B |
Dividend Yield | — | 3.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
Consolidated Edison (ED) trades at $111.12, up 0.76% on the day, with a bullish technical signal from moving averages and support near $110. The company reported revenue of $16.92B in 2025 with a net income margin of 12.52%, though Q1 2026 EPS missed expectations. Recent news highlights grid upgrades for AI data center demand and a new board member appointment, reinforcing its steady utility profile.
ED offers a defensive investment with a 3.3% dividend yield and 52-year growth streak, but faces risks from capital-intensive grid expansions and interest rate sensitivity. Analyst consensus is cautious with a $103.50 price target below current levels, suggesting limited near-term upside amid high hold ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Consolidated Edison, Inc.
Con Ed is a holding company for Consolidated Edison of New York, or CECONY, and Orange & Rockland, or O&R. These utilities provide steam, natural gas, and electricity to customers in southeastern New York—including New York City—and small parts of New Jersey. The two utilities will generate nearly all of Con Ed's earnings once it closes the sale of its clean energy business to RWE. Con Ed's clean energy business owns the second-largest portfolio of utility-scale solar projects in the U.S. Following the sale, Con Ed's only non-utility earnings will come from investments in gas and electric transmission.
Read more on ED →
